Bone metastases predict worse outcomes in patients with metastatic urothelial carcinoma (mUC) treated with single-agent immunotherapy, investigators reported at the virtual 2021 Genitourinary Cancers Symposium.
The findings are from a retrospective study of 208 patients, of whom 86 (41%) had bone metastases and 122 (59%) did not. Patients received single-agent immunotherapy after experiencing disease progression despite prior chemotherapy.
Of this cohort, 13% had disease progression within 12 months after receiving adjuvant or neoadjuvant chemotherapy, and 79% had disease progression after a previous line of platinum-based chemotherapy for advanced disease.
The bone-metastases group had shorter progression-free survival (median 2.0 vs 2.6 months) and overall survival (median 3.9 vs 7.8 months) compared with patients who did not have bone metastases, Patrizia Giannatempo, MD, of IRCCS National Cancer Institute Foundation in Milan, Italy, and colleagues reported.
Patients without bone metastases were more likely than those with bone metastases to be alive after 6, 12, and 24 months: 62% vs 40%, 38% vs 23%, and 24% vs 13%, respectively.
On multivariable analysis, bone metastases was significantly associated with 76% and 79% increased risks for disease progression and death, respectively, compared with the absence of bone metastases, according to the investigators.
Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors’ disclosures.
Giannatempo P, Marandino L, Raggi D, et al. A multicenter, retrospective study on impact of immunotherapy in urothelial carcinoma with bone metastases (Meet-Uro01 Study). Study presented at the virtual 2021 Genitourinary Cancers Symposium, February 11 to 13. Abstract 401.